We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is PDL BioPharma (PDLI) Up 5.3% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for PDL BioPharma (PDLI - Free Report) . Shares have added about 5.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
PDL BioPharma delivered earnings of 9 cents per share in the third quarter of 2019, beating the Zacks Consensus Estimate of 4 cents. The bottom line was also higher than the year-ago figure of 7 cents.
The company’s total revenues grossed $44.2 million in the third quarter, mainly attributable to higher product sales and royalty rights. However, revenues plunged 34.9% year over year.
Quarter in Detail
Product revenues in the quarter were $20.3 million, down 16.8% year over year. The same included $12.2 million from the sales of Noden products, namely Tekturna and Tekturna HCT and another $8.1 million from the sales of LENSAR laser system in the United States.
Notably, revenues from LENSAR laser system increased 22% year over year and also 9% sequentially. Per the company, majority of its top-line growth was owing to revenues recognized from the ex-U.S. markets. Besides, in the third quarter, LENSAR procedure volume expanded 28% year over year.
PDL recognized $23.9 million in net royalty revenues and revenues from royalty rights reflecting a 43.3% drop year over year.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is PDL BioPharma (PDLI) Up 5.3% Since Last Earnings Report?
It has been about a month since the last earnings report for PDL BioPharma (PDLI - Free Report) . Shares have added about 5.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
PDL BioPharma Q3 Earnings Beat, LENSAR Drives Sales
PDL BioPharma delivered earnings of 9 cents per share in the third quarter of 2019, beating the Zacks Consensus Estimate of 4 cents. The bottom line was also higher than the year-ago figure of 7 cents.
The company’s total revenues grossed $44.2 million in the third quarter, mainly attributable to higher product sales and royalty rights. However, revenues plunged 34.9% year over year.
Quarter in Detail
Product revenues in the quarter were $20.3 million, down 16.8% year over year. The same included $12.2 million from the sales of Noden products, namely Tekturna and Tekturna HCT and another $8.1 million from the sales of LENSAR laser system in the United States.
Notably, revenues from LENSAR laser system increased 22% year over year and also 9% sequentially. Per the company, majority of its top-line growth was owing to revenues recognized from the ex-U.S. markets. Besides, in the third quarter, LENSAR procedure volume expanded 28% year over year.
PDL recognized $23.9 million in net royalty revenues and revenues from royalty rights reflecting a 43.3% drop year over year.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.